The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India. The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.
Source-Medindia